Login to Your Account



Other News To Note


Wednesday, October 31, 2012
• Complix NV, of Hasselt, Belgium, was awarded a grant of €1.9 million (US$2.4 million) from the Flanders government through the Agency for Innovation by Science and Technology in Flanders to speed up development of its cell penetrating alphabodies (CPABs) for a number of disease targets, including cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription